Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSCs for Xerostomia After Radiation Therapy for Head and Neck Cancer
NCT04489732Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Feb 2022
- Primary completion
- Nov 2022
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Provacel in xerostomia, sponsored by University of Wisconsin–Madison. Primary endpoint: Percentage of Subjects Experiencing Dose Limiting Toxicity at 1 month. Started Feb 2022; status: completed.
02
Drugs
Provacel
03
Conditions
xerostomia
Beyond the preview
Go deeper on NCT04489732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04489732.